Referral Form: |
WHAT IT TREATS: Ankylosing SpondylitisCrohn’s DiseaseCytokine Release SyndromeGeneralized Pustular PsoriasisGiant Cell ArteritisHunter SyndromeInflammatory Bowel DiseaseJuvenile Idiopathic ArthritisKawasaki DiseaseNon-radiographic Axial SpondyloarthritisPsoriasisPsoriatic ArthritisSpondyloarthropathiesStill’s DiseaseUlcerative Colitis |
MANUFACTURER: Remicade: Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) Renflexis: Samsung Bioepis |
CLASS: Remicade: Tumor Necrosis Factor (TNF) Inhibitor, Monoclonal Antibody (Biologic Therapy)
Renflexis: Infliximab injection products are in a class of medications called tumor necrosis factor-alpha (TNF-alpha) inhibitors. |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Remicade: Three times in the first six weeks, then every eight weeks Renflexis: Every eight weeks after an initial induction phase of doses given at weeks zero, two, and six |
Length of infusion: About two hours |
Related drugs
